Kawin

Beijing Kawin Technology Share-holding Co., Ltd. (hereinafter referred to as "Kawin") was established in 2008 with a registered capital of RMB 115 million. Located in the Beijing Economic-Technological Development Area, a national-level economic and technological development zone known as the "Pharma Valley," Kawin is a biopharmaceutical company that leverages technology as its platform and is dedicated to providing therapeutic solutions for viral diseases. With biotechnology as its foundation, Kawin focuses on the field of liver diseases, offering comprehensive treatment solutions.Kawin operates two manufacturing sites comprising a total of seven new GMP-compliant production workshops for biological products and chemical pharmaceuticals. Among these, the biological and chemical injectables workshops have obtained international GMP certification from INVIMA (aligned with WHO standards). The company boasts diverse production lines for various drug dosage forms. The biological product lines include small-volume injections (non-terminally sterilized), lyophilized powder for injection, and effervescent tablets. The chemical pharmaceutical lines encompass small-volume injections (both terminally and non-terminally sterilized), lyophilized powder for injection, tablets, and capsules. Notably, the production line for terminally sterilized chemical injectables has achieved international GMP certification from Ukraine (aligned with PIC/S standards).Kawin’s main products include Recombinant Human Interferon α2b Injection (Kawinyisheng), Compound Glycyrrhizin Capsules (Kawinganle), and Recombinant Human Interferon α2b Vaginal Effervescent Tablets (Jinshuxi).